Safety of direct oral anticoagulants reversal agents in older patients: an analysis of individual case safety reports of adverse drug reaction from VigiBase®
Authors:
- Giada CrescioliGiada Crescioli
- Niccolò LombardiNiccolò Lombardi
- Elena ArzentonEAElena Arzenton
- Nicoletta LuxiNLNicoletta Luxi
- Stefano FumagalliSFStefano Fumagalli
- Roberto BonaiutiRBRoberto Bonaiuti
- Costanza CaciniCCCostanza Cacini
- Guido MannaioniGMGuido Mannaioni
- Gianluca TrifiròGTGianluca Trifirò
- Ugo MorettiUMUgo Moretti
- Alfredo VannacciAlfredo Vannacci
Open Access
- 7 April 2025
- journal article
- research article
- Published by Springer Nature in Aging Clinical and Experimental Research
- Vol. 37 (1) , 1-10
Abstract
Background: Real-world data on adverse drug reactions (ADRs) associated with idarucizumab and andexanet alfa are limited. Aim: This study aimed to assess the frequency, the characteristics and clinical and demographic factors associated with ADRs related to their use. Methods: This is a retrospective analysis of ADR reports collected in Vigibase® until May 31, 2023. Multivariable logistic regression estimated reporting odds ratios (RORs) for serious ADRs, death, and thromboembolic events according to demographical and clinical covariates. Results: A total of 1095 Individual Case Safety Reports (ICSRs) reporting idarucizumab (72%) or andexanet alfa (28%) as suspected/interacting agents were collected. Most of the subjects were males (44.5%), with a median age of 78 years, and exposed to only one suspected/interacting medication (73.6%). ADRs were defined as serious in 88.6% of cases, with a total of 614 (56.1%) fatal cases. Compared to patients without concomitant medications, probability of serious ADRs and death were both higher in those receiving ≥ 5 concomitant medications in the idarucizumab subgroup (ROR 4.04 and 1.66, respectively) and in those receiving 1–4 concomitant medications in the andexanet alfa subgroup (ROR 5.66 and 4.80, respectively). Moreover, the probability of thromboembolic events was significantly lower for subjects aged > 75 years (ROR for 75–84 years 0.55; ROR for ≥ 85 years 0.50). Discussion: In real-world, ADRs associated with idarucizumab and andexanet alfa use are generally serious, resulting in death in a high percentage of subjects. Conclusion: Clinicians should pay particular attention when managing individuals needing these drugs, especially if vulnerable and requiring polytherapy.Keywords
Funding Information
- Università degli Studi di Firenze
This publication has 46 references indexed in Scilit:
- A Risk-Based Approach for Safety Case Follow-up of Adverse Event Reports in PharmacovigilanceAdvances in Therapy, 2023
- Suspected adverse reactions to medications and food supplements containing Serenoa repens: A worldwide analysis of pharmacovigilance and phytovigilance spontaneous reportsPhytotherapy Research, 2023
- Factors Associated with Underreporting of Adverse Drug Reactions by Health Care Professionals: A Systematic Review UpdateDrug Safety, 2023
- Evaluation of Direct Oral Anticoagulant Reversal Agents in Intracranial HemorrhageJAMA Network Open, 2022
- A New Era in Pharmacovigilance: Toward Real‐World Data and Digital MonitoringClinical Pharmacology & Therapeutics, 2021
- Adverse drug reactions in SARS-CoV-2 hospitalised patients: a case-series with a focus on drug–drug interactionsInternal and Emergency Medicine, 2020
- Risk of hospitalisation associated with benzodiazepines and z-drugs in Italy: a nationwide multicentre study in emergency departmentsInternal and Emergency Medicine, 2020
- Real World Outcomes Associated with Idarucizumab: Population-Based Retrospective Cohort StudyAmerican Journal of Cardiovascular Drugs, 2019
- Age-related changes in the hemostatic systemInternational Journal of Clinical and Laboratory Research, 1993
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987